Skip to main navigation Skip to search Skip to main content

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

  • Ruth Ladenstein
  • , Ulrike Pötschger
  • , Dominique Valteau-Couanet
  • , Roberto Luksch
  • , Victoria Castel
  • , Isaac Yaniv
  • , Geneviéve Laureys
  • , Penelope Brock
  • , Jean Michon
  • , Cormac Owens
  • , Toby Trahair
  • , Godfrey Chi Fung Chan
  • , Ellen Ruud
  • , Henrik Schroeder
  • , Maja Beck-Popovic
  • , Günter Schreier
  • , Hans Loibner
  • , Peter F Ambros
  • , Keith Holmes
  • , Maria Rita Castellani
  • Mark Gaze, Alberto Garaventa, Andrew DJ Pearson, Holger N Lode
  • Department Oncology, St. Anna Children’s Hospital
  • Hospital Universitario y Politécnico de La Fe
  • Sydney Children's Hospital
  • Department of Paediatrics, University Hospital of Aarhus
  • St. Anna Children’s Cancer Research Institute (CCRI)

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1617-1629
Number of pages13
JournalLancet Oncology
DOIs
Publication statusPublished - 2018

Research Field

  • Exploration of Digital Health

Cite this